A two-part Phase II study of cediranib in patients with advanced solid tumours: The effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 3, 2011, Pages 631-641

  Mitchell, Claire L ^a   O'Connor, J P B ^a,b   Roberts, C ^b   Watson, Y ^b   Jackson, A ^b   Cheung, S ^b   Evans, J ^c   Spicer, J ^d   Harris, A ^e   Kelly, C ^c   Rudman, S ^d   Middleton, M ^e   Fielding, A ^f   Tessier, J ^f   Young, H ^f   Parker, G J M ^b   Jayson, G C ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Cediranib; CT enhancement; DCE MRI; Food; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; CEDIRANIB; THYROTROPIN; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; CHEMOTHERAPY INDUCED EMESIS; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPHONIA; EXPLORATORY RESEARCH; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HYPERTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SORE THROAT; STOMATITIS; T WAVE; THYROTROPIN BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80054715969     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1534-3     Document Type: Article

References (25)

1. SR Wedge J Kendrew LF Hennequin, et al. 2005 AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 4389 4400 15899831 10.1158/0008-5472.CAN-04-4409 1:CAS:528:DC%2BD2MXktlSmtLs%3D
2. TT Batchelor AG Sorensen E di Tomaso, et al. 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 17222792 10.1016/j.ccr.2006.11.021 1:CAS:528:DC%2BD2sXhtFClsLc%3D
3. J Drevs P Siegert M Medinger, et al. 2007 Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Clin Oncol 25 3045 3054 17634482 10.1200/JCO.2006.07.2066 1:CAS:528:DC%2BD2sXptlGrsbo%3D
4. Mulders P, Hawkins R, Nathan P, de Jong I, Mookerjee B, Osanto S, Pike L, Porfiri E, Protheroe A, Gore ME (2008) Cediranib (RECENTIN™) in patients with advanced renal cell carcinoma: results of a randomized Phase II study. In: 7th International kidney cancer symposium, Edition
5. Matulonis U, Berlin S, Krasner C, Tyburski K, Lee J, Roche M, Ivy P, Penson R (2007) Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer. Mol Cancer Ther 6:abst 263
6. Sridhar SS, Mackenzie MJ, Hotte SJ et al. (2008) Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium. J Clin Oncol (Meeting Abstracts) 26:261s, abstr 5047
7. SA Laurie I Gauthier A Arnold, et al. 2008 Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 26 1871 1878 18398152 10.1200/JCO.2007.14.4741 1:CAS:528:DC%2BD1cXmsFemtr0%3D
8. Shields A, Heath E, DeLuca P, Pilat M, Wozniak A, Gadgeel S, Puchalski T, Xu J, Liu Q, LoRusso P (2007) AZD2171 in combination with various anticancer regimens: follow-up results of a phase I multi-cohort study. J Clin Oncol 25 (18S):abst 3544
9. JP O'Connor A Jackson GJ Parker GC Jayson 2007 DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 189 195 17211479 10.1038/sj.bjc.6603515
10. B Morgan AL Thomas J Drevs, et al. 2003 Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 3955 3964 14517187 10.1200/JCO.2003.08.092 1:CAS:528:DC%2BD2cXpsVajsbw%3D
11. G Liu HS Rugo G Wilding, et al. 2005 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study J Clin Oncol 23 5464 5473 16027440 10.1200/JCO.2005.04.143 1:CAS:528:DC%2BD2MXhtVersr7E
12. JP O'Connor GC Jayson A Jackson, et al. 2007 Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma Clin Cancer Res 13 6130 6135 17947478 10.1158/1078-0432.CCR- 07-0331
13. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
14. NC Ton GJ Parker A Jackson, et al. 2007 Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2 Clin Cancer Res 13 7113 7118 18056191 10.1158/1078-0432.CCR-07-1550 1:CAS:528:DC%2BD2sXhtlyitLzF
15. SA Mullamitha NC Ton GJ Parker, et al. 2007 Phase I evaluation of a fully human anti-alpha v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors Clin Cancer Res 13 2128 2135 17404096 10.1158/1078-0432. CCR-06-2779 1:CAS:528:DC%2BD2sXjs12rt7k%3D
16. JPB O'Connor RAD Carano AR Clamp, et al. 2009 Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 6674 6682 19861458 10.1158/1078-0432.CCR-09- 0731
17. PS Tofts 1997 Modeling tracer kinetics in dynamic Gd-DTPA MR imaging J Magn Reson Imaging 7 91 101 9039598 10.1002/jmri.1880070113 1:STN:280: DyaK2s7ptFKmsA%3D%3D
18. Parker G, Jackson A, Waterton JC, Buckley DL Automated Arterial Input Function Extraction for T1-Weighted DCE-MRI. In: Proceedings International Soc. Mag. Reson. Med. Edition, abst 1264
19. GJ Parker C Roberts A Macdonald, et al. 2006 Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI Magn Reson Med 56 993 1000 17036301 10.1002/mrm.21066
20. JL Evelhoch 1999 Key factors in the acquisition of contrast kinetic data for oncology J Magn Reson Imaging 10 254 259 10508284 10.1002/(SICI)1522- 2586(199909)10:3<254::AID-JMRI5>3.0.CO;2-9 1:STN:280:DyaK1Mvjsl2jug%3D%3D
21. C Rorden M Brett 2000 Stereotaxic display of brain lesions Behav Neurol 12 191 200 11568431
22. HS Rugo RS Herbst G Liu, et al. 2005 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results J Clin Oncol 23 5474 5483 16027439 10.1200/JCO.2005.04.192 1:CAS:528:DC%2BD2MXhtVersr7F
23. Batchelor T, Duda DG, di Tomaso E, Kozak K, Zhang W-T, Ancukiewicz M, Loeffler JS, Wen P, Sorensen G, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. In: Proceedings Am. Assoc. Cancer Res. 48, Edition
24. T Trarbach J Drevs D Strumberg TC Gauler V Schneider WE Eberhardt M Marotti TA Puchalski AJ Swaisland 2008 A phase I, open-label, multicenter study of cediranib and AZD0530 in patients with advanced solid tumors J Clin Oncol 26 15S 175S (abst 3592)
25. Langenberg M, van Herpen CM, de Bono JS, Unger C, Schellens JH, Hoekman K, Blum HE, Le Maulf F, Fielding A, Voest EE (2008) Optimal management of emergent hypertension during treatment with a VEGF signaling inhibitor: a randomized phase II study of cediranib. J Clin Oncol 26:abst 3555